Consider my comparison's time-line and then perhaps rephrase.
200? Can we get back to 5 first lol. -beleiver20
I'm referencing CTIX being at a similar stage of development with at least two Phase 3 trials, one of them Kevetrin. Possibly more, and a buy-out in play. It is a forward looking post. (See disclaimer)
For the record, I expect to see $5 in the rear-view mirror well prior to that. By my calculations CTIX is undervalued now. We had some extra selling this last Spring and the up-listing delay after all, accompanied by considerable whinging. But ZERO clinical set-backs.
No, we're not there yet. But with one Phase 3 soon to start, two Phase 2's up and running with one or two more likely soon, CTIX could be a two Phase 3 and one Phase 2 company relatively soon. Quite possibly more.
Assuming that sort of clinical success, I seriously doubt we'll be discussing single digit share price numbers. If one of those Phase 3 clinical trials is Kevetrin... boom.
But yes, I know, we must pass $9 to get to $10 and so on. Just as when CTIX was 0.30 it indeed had to pass 0.40 before the decimal point moved once to the right.
As I recall, CTIX traded near the current share price with just one drug at the beginning of Phase 1 and no other clinical trials. Now that drug is near the successful end of Phase 1, a new drug is soon to enter Phase 3 with a Phase 2 up and running for a separate indication. Another drug, Prurisol, has completed Phase 1 and is now in Phase 2. The pipeline has also greatly increased.
Yes, I believe CTIX is very undervalued right now and the share price is not accurately reflecting the clinical developments. I also believe CTIX has significant potential for a much higher share price in the coming months and years.
And yes, seeing large buy-outs of other companies at, or below the level where CTIX is headed gives me reason for increased confidence that with clinical success CTIX will get there as well.
News 
Market Data 
Discover 
AI
